Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.

@article{Sivolella2013DenosumabAA,
  title={Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.},
  author={Stefano Sivolella and Franco Lumachi and Edoardo Stellini and Lorenzo Favero},
  journal={Anticancer research},
  year={2013},
  volume={33 5},
  pages={1793-7}
}
Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw characterized by exposed necrotic bone and is related to several drugs usually used for treating patients with advanced malignancies. Common therapies inducing ONJ are nitrogen-containing bisphosphonates (BPs), the human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand denosumab and some anti-angiogenic drugs, alone or in combination with BPs. The real incidence of ONJ is unknown. Several cases… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Osteonecrosis of the jaws and bevacizumab therapy : A case report

  • P BrunamontiBinello, R Bandelloni, M Labanca, B Buffoli, R Rezzani, LF Rodella
  • Int J Immunopathol Pharmacol
  • 2012

Similar Papers

Loading similar papers…